Analysts' Top 5 Price Targets of March 2, 2026
Reading Time: 3 minutes
Palvella Therapeutics [US6979471090] Clear Street reaffirms Buy rating and raises the price target from $200 to $220 (62% upside potential) Key to the positive assessment are the impressive Phase 3 data from the SELVA study, where the drug Qtorin Rapamycin has shown strong efficacy against microcystic lymphatic malformations. According to experts, these results optimally position Palvella for a highly promising FDA approval. Qtorin Rapamycin has the potential to become the first approved therapy for the approximately 30,000 US patients with...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
